Gammaglobulin non-sensitive Kawasaki disease is currently clinically advocated to be treated again with intravenous infusion of high-dose gammaglobulin, or treated with glucocorticoids, or gammaglobulin combined with glucocorticoids. The full name of Kawasaki disease is Pediatric Cutaneous Mucocutaneous Lymph Node Syndrome, which is caused by systemic vasculitis, with fever, skin rash, mucosal congestion, and enlarged lymph nodes as the main symptoms, and usually occurs in children. The exact cause of the disease is unclear and may be related to infection and genetics. Kawasaki disease is usually treated with medications, and aspirin combined with gammaglobulin is commonly used clinically. Gammaglobulin-naïve Kawasaki disease, also known as gammaglobulin-naïve Kawasaki disease, is usually characterized by persistent fever 36 hours after the use of intravenous high-dose gammaglobulin infusion, or by a reoccurrence of fever after the fever has subsided. In this case, another intravenous infusion of high-dose gammaglobulin is currently advocated, which can increase the level of the drug in the child’s blood and enhance the anti-inflammatory effect. Glucocorticosteroids can also be used for treatment, or the use of gammaglobulin combined with glucocorticosteroids. Parents are advised to bring their children to the doctor in time, explain their children’s situation, choose the appropriate treatment according to the professional doctor’s advice, and take the medication according to the doctor’s instructions, so as to avoid adverse consequences.